BiotechTV: Using NK Cell Therapies for Autoimmune Disease and Cancer with Artiva’s CEO
Fred Aslan describes how Artiva is harnessing the ability of NK cells to act as a modulator of antibody dependent cellular cytotoxicity as a therapeutic property of its cell therapies.
Watch the interview here.